PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. in a Transaction Valued at Over $100 Million
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders
PharmAla To Supply Amsterdam UMC with LaNeo MDMA, Including Development of New Single-Capsule Stability Data
Brixton Metals Enters into Option Agreement to Acquire a 100% Interest in the Silver Focused Silvergruvan Project in Sweden
Nevada Sunrise Announces Results of Soil Sampling Program at the Fivemile Gold Project, Cortez Mining District, Nevada
SAGA Metals Drills 485.4 m at 32.21% Fe2O3, 5.30% TiO2, 0.191% V2O5 Including 56.8 m at 49.56% Fe2O3, 8.17% TiO2, 0.339% V2O5 at Radar Critical Minerals Project in Labrador
